Skip to main content

Table 1 Demographic and clinicopathologic characteristics of melanoma patients treated with immunotherapy

From: Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy

Variable

Number of patients (n = 71)

Age at diagnosis (years)

  Median (Range)

55 (21–80)

Gender

 

  Male

40 (56.3%)

  Female

31 (43.7%)

AJCC stage at diagnosis

  I

5 (7.1%)

  II

26 (36.6%)

  III

40 (56.3%)

Primary TILs

 

  Absent

16 (22.6%)

  Present

52 (73.2%)

   Non-brisk

29

   Brisk

23

  Unclassified

3 (4.2%)

Immunotherapy setting a

 

  Adjuvant

40 (56.3%)

  At Recurrence

31 (43.7%)

Type of immunotherapy

  Immune biologic

38 (53.5%)

   IFN-α

21

   IL-2, IL-18

4

   GM-CSF

12

   Other

1

  Vaccine

33 (46.5%)

   Dendritic cell

11

   Peptide

22

  1. Abbreviations: AJCC American joint committee on cancer, TILs Tumor-infiltrating lymphocytes, NOS Not otherwise specified.
  2. aPatients who received immunotherapy in both settings (n=6).
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us